XBRANE BIOPHARMA'S PRINCIPAL OWNER SYSTEMATIC GROUP PROVIDES A SHORT-TERM LOAN OF SEK 20 M TO THE COMPANY

MAR

Xbrane Biopharma AB (publ) ("Xbrane" or the "Company") has today received a short-term loan from Systematic Group AB ("Systematic Group") of SEK 20 million (the "Loan").

The loan provided by Systematic Group amounts to SEK 20 million and runs for approximately 1 month until the expected up-front payment of €10 million from Intas Pharmaceuticals Ltd, in accordance with the previously communicated license agreement for Xdivane (Opdivo biosimilar candidate), is received. Interest is charged at 1 percent per month. The loan will finance the company's working capital needs until the above-mentioned up-front payment is received.

Datum 2024-12-02, kl 14:30
Källa MFN
Investera som eToros bästa investerare! Med eToros CopyTrader™, kan du automatiskt kopiera andra investerares beslut. Hitta investerare som du tror på och kopiera deras investeringar i realtid. Inga extra avgifter tas ut för funktionen.
Copy Trading innebär inte investeringsrådgivning. Värdet på dina investeringar kan gå upp eller ner. Du riskerar ditt kapital.